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Atherosclerosis is the major cause of death and disability. Atherosclerotic plaques are characterized by a
chronic sterile inﬂammation in the large blood vessels, where lipid-derived and damage-associated
molecular patterns play important roles in inciting immune responses. Following the initial demon-
stration that NLR family Pyrin domain containing 3 (NLRP3) was important for atherogenesis, a sub-
stantial number of studies have emerged addressing the basic mechanisms of inﬂammasome activation
and their relevance to atherosclerosis. In this review, we introduce the basic cellular and molecular
mechanisms of NLRP3 inﬂammasome activation, and discuss the current ﬁndings and therapeutic
strategies that target NLRP3 inﬂammasome activation during the development and progression of
atherosclerosis.
Crown Copyright © 2017 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Atherosclerosis
Atherosclerosis is the leading cause of death in the developed
societies. Atherosclerosis is a progressive cardiovascular disease
with lipid deposition in large arteries at areas of disturbed ﬂow,
resulting in the formation of atherosclerotic plaques. Plaque
rupture or erosion can cause acute cardiovascular events, such as
heart attack and stroke. Inﬂammation plays an important role, both
in the development and complications of atherosclerosis [1,2]. In
particular, inﬂammasome pathways have been extensively
explored in the past decade and shown to be involved in regulating
multiple inﬂammatory diseases, including atherosclerosis [3]. The
rationale for the CANTOS trial testing the efﬁcacy of IL-1b blockade
in patients with coronary artery disease was largely based on the
role of inﬂammasome-mediated activation of IL-1b in experimental
models of atherosclerosis. Hence, the regulation of inﬂammasome
activity in atherosclerosis has been largely explored at multiple
levels.University of Cambridge, The
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vier Ireland Ltd. This is an open acc1.2. NLRP3 inﬂammasome and its canonical activation
Inﬂammasomes are multiprotein signalling complexes. They
play key roles in the mediation of innate inﬂammatory responses
and are assembled in response to a wide range of stimuli including
both PAMPs (Pathogen-Associated Molecular Patterns) and DAMPs
(Damage-Associated Molecular Patterns).
Among all inﬂammasomes, NLRP3 has been more extensively
studied and characterized, because of its crucial role in immunity
and inﬂammation [4,5]. The key components of this signalling
platform are NLRP3 protein, its adaptor protein ASC (apoptosis-
associated speck-like protein containing a CARD), and Caspase-1,
which is cleaved by this multiprotein complex. Cleavage of pro-
Caspase-1 yields active Caspase-1, a proteolytic enzyme that in
turn cleaves the pro-inﬂammatory cytokines IL-1b and IL-18 into
their active forms, which induce inﬂammatory responses.
Apart from release of pro-inﬂammatory signals, canonical
inﬂammasome activation leads to a special form of cell death called
pyroptosis. Pyroptosis, or Caspase-1-dependent cell death, is a
cellular program of self-destruction. Caspase 1 cleaves Gasdermin
D, and active Gasdermin D oligomers form membrane pores lead-
ing to loss of cell integrity [6]. Pyroptosis is associated with the
release of mature IL-1b and IL-18, and is characterized by cellular
swelling and lysis [7]. Both cytokines can be released with different
mechanisms, such as: (1) secretion through pores [7], (2) shedding
in microvesicles [8,9] and (3) lysosome-mediated exocytosis [10].
Furthermore, with loss of cell integrity, more DAMPs are releasedess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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nals lead to further activation of the immune response.
NLRP3 inﬂammasome activation has been more extensively
studied in macrophages, but it has been described in other cell
types as well, including smoothmuscle cells (SMC) [11], endothelial
cells [12] and T cells [13e17]. Moreover, the roles of NLRP3 may
extend beyond the regulation of the inﬂammasome pathway or
innate immune responses. For example, NLRP3 is important for
Th17 differentiation in a ASC-dependent manner [16,17] and NLRP3
can also behave as a transcriptional regulator, to drive
inﬂammasome-independent Th2 differentiation [14]. In addition,
NLRP3 activation in CD4þ human T cells promotes autocrine Th1
differentiationwith amechanism that is dependent on activation of
the intracellular C5a receptor 1 [18].
1.3. Molecular and cellular players involved in the regulation of
canonical NLRP3 inﬂammasome priming and activation
In canonical NLRP3 inﬂammasome activation, two signals, a
priming signal and an activation signal, are necessary for activation
of NLRP3. This dual requirement acts as a safeguarding mechanism
that tightly controls inﬂammatory cell activation.
NLRP3 is present at low levels in all myeloid cells but its
expression increases when cells are primed in response to stimuli
[19,20]. The priming signal induces the expression of NLRP3 and
pro-IL-1b at the transcriptional level through activation of the NF-
kB pathway [20]. The priming step can be modulated by both post-
transcriptional and post-translational modiﬁcations of NLRP3.
Post-transcriptional modulation of NLRP3 expression can occur
by regulatory RNA such as the negative regulator miR-223, a
myeloid-speciﬁc microRNA that shows different expression levels
acrossmyeloid cell types. miR-223 suppresses NLRP3 expression by
binding to a conserved region of its sequence [21]. Furthermore,
recent evidence points to a role of the RNA-binding protein Tris-
tetraprolin (TTP), which acts as a negative regulator of NLRP3 in
human macrophages by binding to NLRP3 30 UTR [22].
Post-translational modiﬁcations of NLRP3 protein play impor-
tant roles in regulating its function. NLRP3 is deubiquitinated upon
priming, leading to reduced proteasomal degradation and hence
increased life span of the protein [23,24]. In mouse macrophages,
deubiquitination is mediated by TLR4 through MyD88 [24]. Modi-
ﬁcation of NLRP3 by nitrosylation occurs upon activation of IFNg
receptor, and it has an inhibitory effect on NLRP3 protein, pre-
venting its oligomerization [25]. The activity of NLRP3 is also
regulated through phosphorylation of different serine sites, with
phosphorylation at serine 5 having a particularly important role in
NLRP3 inﬂammasome inhibition [26]. Phosphatase PP2A can de-
phosphorylate NLRP3 leading to its activation [26].
The activation step of NLRP3 inﬂammasome is under intense
investigation. A wide range of stimuli converges on NLRP3
inﬂammasome complex for full activation, indicating that there are
multiple pathways and players involved. A simple model of direct
interaction of the different signals with NLRP3 protein is very un-
likely, because of the diversity and variety of NLRP3 inﬂammasome
activating stimuli [27,28].
Potassium efﬂux has emerged as a key step leading to inﬂam-
masome activation, but the precise link between the efﬂux of po-
tassium ions and NLRP3 inﬂammasome assembly is not completely
understood [29]. When potassium efﬂux is inhibited, NLRP3
inﬂammasome activation and IL-1b maturation are compromised
[30,31]. Activating stimuli that are dependent on potassium ions
efﬂux include: (1) extracellular ATP, by activation of the non-
selective P2X7 cation channel, which results in localized Kþ
efﬂux from macrophages, in proximity to the site of activation [32,
33]; (2) Kþ efﬂux agonists such as the bacterial ionophore nigericin[34]; (3) bacterial pore-forming toxins [29]; (4) some antibiotics,
including neomycin, polymyxin B, gramicidin and tyrothricin [35].
Tschopp and colleagues initially proposed a model in which
different NLRP3-activating stimuli converge on mitochondria,
resulting in excessive production of Reactive Oxygen Species (ROS),
which then trigger inﬂammasome activation [36,37]. Stimuli that
converge on ROS production include ATP [36], asbestos [38], silica
[38], and endoplasmic reticulum (ER) stress [39]. Autophagy and
mitophagy may regulate this pathway by removing damaged
mitochondria, and impairment of mitophagy is suggested to trigger
inﬂammasome activation through accumulation of ROS species
[37,40]. However, production of ROS by mitochondria may not be a
universal mechanism of inﬂammasome activation, but rather by-
products of NLRP3 inﬂammasome activation [29,41].
Lysosome damage occurs upon cellular intake of crystals, such
as cholesterol crystals [3,42], silica and monosodium urate (MSU)
crystals [38,43]. Lysosome damage activates the NLRP3 inﬂamma-
some through the release of cathepsins [44], which may act as a
converging mechanism in regulating particle-induced inﬂamma-
some activation. Other proposed regulatory mechanisms of NLRP3
inﬂammasome activation involve aberrant calcium signalling
[45,46], and regulation of P2X7 receptor signalling [47].
Integrity of the cellular microtubule network is crucial for
inﬂammasome activation [48,49]. Low NADþ levels trigger
inﬂammasome activation by preventing SIRT2 activation, leading to
accumulation of acetylated a-tubulin, a mediator of mitochondrial
transport [48]. More importantly, NLRP3 is transported along the
microtubules to access mitochondria, then reaches the
microtubule-organizing centre, where it forms the stereotypical
inﬂammasome complex speck structure, which ensures an optimal
inﬂammasome activation [49]. Shear stress is also known to affect
the actin cytoskeleton in endothelial cells [50]. In particular, F-actin
has an inhibitory role on NLRP3 inﬂammasome activation [51] and
it is therefore likely that this protein is involved in licensing of the
NLRP3 inﬂammasome upon shear stress. Consistent with this hy-
pothesis, cell swelling, a process that leads to a decrease in F-actin
levels [52], results in NLRP3 inﬂammasome activation [53].
A variety of novel players have been identiﬁed recently, that
directly interact with NLRP3 and modulate its function: (1) Gua-
nylate Binding Protein 5 (GBP5), a selective activator of NLRP3
inﬂammasome assembly, binds directly to NLRP3 to promote ASC
assembly via a PYD/CARD interaction in response to soluble (but
not crystalline) danger signals [54]; (2) the mitochondrial adaptor
Mitochondrial Antiviral Signalling Protein (MAVS), which interacts
with the N-terminal domain of NLRP3 and is crucial for correct
mitochondrial localization and optimal inﬂammasome activation
[55]; (3) NimA-related protein kinase 7 (NEK7), which acts down-
stream of the Kþ efﬂux stimulus, interacts with NLRP3 and is
essential for NLRP3 inﬂammasome assembly during interphase
[56e58]; (4) Microtubule afﬁnity regulating kinase 4 (MARK4) in-
teracts with NLRP3, driving it to the microtubule organizing centre,
and is crucial to ensure that one single speck complex is formed in
each cell upon inﬂammasome activation. Interaction of NLRP3 with
MARK4 enables correct subcellular localization of the inﬂamma-
some complex [49].
1.4. Non-canonical inﬂammasome activation
An alternative mechanism resulting in Caspase-1 cleavage is
non-canonical inﬂammasome activation, which also leads to cell
death (pyroptosis) and release of pro-inﬂammatory signals. Non-
canonical activation occurs with a mechanism that targets
Caspase-11 in mice or Caspase-4 and Caspase-5 in humans. It is
triggered by a speciﬁc subset of activating stimuli, particularly
intracellular LPS of Gram negative bacteria, such as E. coli, C.
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only Caspase-1 independent pyroptosis but also Caspase-1-
dependent release of the pro-inﬂammatory cytokines IL-1b and
IL-18 [59]. Non-canonical inﬂammasome activation occurs inde-
pendently of TLR4, because intracellular LPS binds directly to
Caspase-11 (in mice) or Caspase 4/5 (in humans) [60,61]. The
impact of non-canonical inﬂammasome activation on atheroscle-
rosis is currently unknown.
2. NLRP3 inﬂammasome and atherosclerosis
2.1. Expression of NLRP3 inﬂammasome components in
atherosclerotic arteries
NLRP3 inﬂammasome components are expressed in endothelial
cells [62], smooth muscle cells (SMCs) [11], and immune cells such
as dendritic cells, monocytes, macrophages [63,64] and T cells
[13,14], although most of the work on atherosclerosis has focused
on the role of inﬂammasome activation in monocytes/macro-
phages. In various rodent atherosclerosis models, high NLRP3 levels
were observed inmonocytes andmacrophages, and were increased
after LPS treatment [63,65]. Patients with coronary atherosclerosis
show high levels of NLRP3 expression in the aorta, with NLRP3
expression correlating with the severity of coronary artery stenosis
[66]. Presence of concomitant risk factors (smoking, hypertension,
diabetes, high Lp(a), high total- or LDL-cholesterol, low HDL-
cholesterol) also correlates with increased NLRP3 protein levels in
the aorta of patients with coronary artery disease [66]. Further-
more, in expression studies comparing carotid atherosclerotic
plaques with normal iliac or mesenteric arteries, mRNA and protein
levels of the inﬂammasome components NLRP3, ASC and Caspase1,
as well as IL-1b and IL-18were found to be signiﬁcantly increased in
carotid plaques compared to healthy arteries [67,68]. Within the
atherosclerotic plaques, NLRP3 and ASC co-stained in the CD68
positive macrophage population, particularly in association with
cholesterol crystal clefts, and the association was also detected in a
fraction of smooth muscle cells [67]. Finally, expression of NLRP3 in
subcutaneous adipose tissue, which was mostly attributed to
macrophages, positively correlated with body mass index and
serum levels of uric acid, and showed independent associationwith
the severity of coronary artery disease [69].
Zhao and colleagues failed to ﬁnd signiﬁcant associations be-
tween NLRP3 polymorphism and predisposition to coronary heart
disease in pre-hypertensive Chinese patients [70]. However, the
cohort examined in this study was very limited. In another epide-
miological study, Zhou and colleagues observed a signiﬁcant as-
sociation between the NLRP3 rs10754558 polymorphism and the
occurrence of coronary heart disease, which also corresponded to
increased serum levels of IL-1b [71]. However, the authors did not
explore the mechanism through which this polymorphism affects
NLRP3 activation.
2.2. Loss of inﬂammasome components during atherosclerosis
(Table 1)
Two murine models have been extensively applied by cardio-
vascular researchers to resolve the mechanisms of atherosclerosis
development. These are Apolipoprotein E-deﬁcient mice (Apoe/)
and LDL receptor deﬁcient mice (Ldlr/), both under a C57BL/6
background. Apoe/mice develop atherosclerosis on either a chow
or high fat diet, whereas Ldlr/ mice develop signiﬁcant athero-
sclerosis only when fed a high fat diet. These two models show
signiﬁcant differences in the mechanisms that lead to high
cholesterol diet-induced atherosclerosis and the choice of one over
the other can signiﬁcantly affect experimental observations [72]. Inthis context, it is interesting to note that the impact of NLRP3
inﬂammasome components on atherosclerosis substantially
differed between the various atherosclerosis models.
In Ldlr/models, Duewell and colleagues found that irradiation
and reconstitution with Nlrp3/, Asc/, or Il1a/ Il1b/ bone
marrow signiﬁcantly reduced the development of atherosclerotic
lesions after 8 weeks of high fat diet in comparison with Ldlr/
mice reconstituted with a control bone marrow [3]. Similarly,
reconstitution of Ldlr/ mice with Caspase-1-deﬁcient bone
marrow signiﬁcantly decreased plaque size after 12 weeks of high
fat diet in comparison with a control bone marrow [73]. Using a
similar bone marrow transplantation model in Ldlr/ mice put on
high fat diet for 16 weeks, Freigang et al. conﬁrmed the role of bone
marrow-derived IL-1a in promoting atherosclerosis. Surprisingly,
they found no impact of bone marrow-derived IL-1b on athero-
sclerosis [74]. However, a close look at their data indicates that mice
with IL-1b deﬁciency developed smaller lesions compared to con-
trols (although not reaching statistical signiﬁcance), and the extent
of lesion development did not signiﬁcantly differ between mice
with IL-1a and IL-1b deﬁciency. Thus, deletion of NLRP3 inﬂam-
masome components reduces atherosclerosis in Ldlr/ mice,
although the effect may be slightly attenuated with long periods of
high fat diet.
Deletion of inﬂammasome components also reduces athero-
genesis in the Apoe/ background, when the mice are analysed
under chow diet. Caspase-1 deletion reduces atherosclerosis [75].
Blockade of IL-18 activity or IL-18 deﬁciency in Apoe/ mice
signiﬁcantly reduced lesion development compared to control an-
imals [76]. Kirii and colleagues found that IL-1b deletion reduced
lesion development by 30% compared to Apoe/ controls [77].
Kamari and colleagues also reported a signiﬁcant 32% reduction of
plaque size for Apoe/ Il1b/ double knockouts and a 52%
reduction for Apoe/ Il1a/mice compared with Apoe/ controls
[78]. Similar observations were reported for irradiated Apoe/
mice reconstituted with Il1a/ or Il1b/ bone marrow [78].
Interestingly, however, feeding Apoe/ a high fat diet substantially
alters the effects of inﬂammasome on atherosclerosis. Caspase-1
deletion still reduces lesion development after 8 weeks on high
fat diet [75], but is unable to do so after 11 weeks on a similar diet
[79]. Similarly, deletion of NLRP3 or ASC has no inﬂuence on lesion
development in Apoe/ after 11 weeks of high fat diet [79].
Consistent with the latter ﬁnding, deletion of Il1r1 was unable to
alter lesion size in Apoe/ fed a high fat diet for 27e30 weeks [80].
Thus, it appears that prolonged high fat feeding tends to limit the
impact of the inﬂammasome on atherosclerosis. The mechanisms
behind this observation are unknown and may include reduced
inﬂammasome activation (e.g., highly nitrosylated NLRP3), a
redundant role of the inﬂammasome (hyperactivation of other
innate immune pathways), or a dispensable role for some inﬂam-
masome targets. For example, IL-1 and IL-18 may substantially
impact atherosclerosis through their roles in the adaptive immune
response, and the latter is dispensable for the development of
atherosclerosis under prolonged and severe hypercholesterolemia
[81,82].
2.3. Priming stimuli of NLRP3 inﬂammasome and their roles in
atherogenesis (Figs. 1 and 2)
TLRs are involved in the delivery of priming signal to enhance
basal expression of NLRP3 and IL-1b in bone-marrow-derived
macrophages (BMDMs) [83]. Most cells in the cardiovascular sys-
tem express TLRs [84]. Different TLRs have different ligand speci-
ﬁcities and therefore detect speciﬁc PAMPs and DAMPs. Increasing
evidence suggest that TLRs are key orchestrators of atherosclerotic
disease processes. Many TLRs are expressed in atherosclerotic
Table 1
Studies on the roles of NLRP3 inﬂammasome and related immune pathways in experimental atherosclerosis.
Molecules Mouse models Diet Cells examined at the lesion Impact on atherosclerosis Ref.
NLRP3 Ldlr/, irradiated and reconstituted with Nlrp3/ bone
marrow
HFD for 8 weeks Macrophages Decrease in early atherosclerosis and IL-18 levels [3]
Apoe/, NLRP3/ HFD for 11 weeks Macrophages and SMCs No impact on inﬂammation or atherosclerosis [79]
IL-1b Ldlr/, irradiated and reconstituted with Il1b/ bone
marrow
HFD for 16 weeks Macrophages IL-1b drives inﬂammation but not atherosclerosis [74]
Ldlr/, irradiated and reconstituted with Il1b/ Il1a/
bone marrow
HFD for 8 weeks Macrophages Rate of atherosclerotic plaques development unaffected
compared to wild type
[3]
Apoe/, Il1b/ Normal diet for 12 weeks or 24 weeks Unspeciﬁed ~30% reduction in atherosclerotic lesion size at 24 weeks [77]
Apoe/, Il1b/ and Apoe/, irradiated and reconstituted
with Il1b/ bone marrow
Normal diet for 16 weeks or 32 weeks Macrophages ~32% reduction in atherosclerotic lesion size [78]
IL-1a Ldlr/, irradiated and reconstituted with Il1a/ bone
marrow
HFD for 8 weeks Macrophages Reduced development of atherosclerotic lesions [3]
Ldlr/, irradiated and reconstituted with Il1a / bone
marrow
HFD for 16 weeks Macrophages Reduced development of atherosclerotic lesions [74]
Apoe/, Il1a/ and Apoe/, irradiated and reconstituted
with Il1a/ bone marrow
Normal diet for 16 weeks or 32 weeks Macrophages ~50% reduction in atherosclerotic lesion size [78]
IL-1r/ Apoe/, Il1r/ HFD for 27e30 weeks Macrophages and SMCs Reduced plaque SMC content, reduced plaque size at the
aortic root, but no difference in plaque size in
brachiocephalic arteries, with greater plaque instability
[80]
Apoeþ/-, Il1r/ and Apoeþ/-, Ilrþ/- HFD for 30 weeks Whole lesion Reduced progression of atherosclerotic plaques [141]
Caspase-1 Ldlr/, caspase-1/11/ HFD for 12 weeks Leukocytes and Macrophages Reduced atherosclerotic plaque size [73]
Apoe/, Caspase1/ HFD for 11 weeks Macrophages and SMCs No impact on inﬂammation or atherosclerosis [79]
Apoe/, Caspase 1/ Saturated fat and cholesterol enriched diet for 8
weeks (compared to low fat diet for 26 weeks)
Whole lesion Decrease in atherosclerosis in both low fat and high fat diet
fed mice
[75]
ASC Ldlr/, irradiated and reconstituted with Asc/ bone
marrow
HFD for 8 weeks Macrophages Marked resistance to development of atherosclerosis [3]
Apoe/, Asc/ HFD for 11 weeks Macrophages and SMCs Reduced plaque layering and adventitial inﬂammation
No impact on overall disease progression
[79]
IL-18 Apoe /, Il18/ Normal diet for 24 weeks SMCs Reduced atherosclerotic plaque size [142]
Apoe/, electro-transferred with IL-18BP plasmid DNA Normal diet for 23 weeks (IL-18BP injection at
14-week old for 9 weeks)
Macrophages,
T cells,
SMCs
Prevention of fatty streak in aorta and slower progression of
atherosclerotic plaques in aortic sinus
[76]
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have been associated with atherosclerosis [85e87]. Most of cell
surface localized (extracellular) TLRs are pro-atherogenic whereas
some endosomal (intracellular) TLRs may be atheroprotective (a
description of the role of key TLRs involved in atherosclerosis is
shown in Table 2).
MyD88 is a key downstream effector of IL1R/TLR signalling.
Total deletion ofMyD88 in Apoe/ background signiﬁcantly limits
atherosclerotic lesion development compared to controls and is
associated with lower circulating levels of pro-inﬂammatory cy-
tokines [88,89]. However, Treg-mediated suppression of athero-
sclerosis requires MyD88 signalling in dendritic cells [55]. Other
signalling adaptors downstream of TLRs also modulate athero-
sclerosis, with TRIF and TRAM being pro-atherogenic in hemato-
poietic cells [90].
Cholesterol crystals [91] can act as danger signals triggering
neutrophils to release Neutrophil Extracellular Traps (NETs),
which will prime macrophages for IL-1b and IL-18 cytokine
release through activation of several TLRs [91,92]. The pro-
inﬂammatory cytokines IL-1b and IL-18 promote further forma-
tion of NETs in a vicious circle [92].
Atherosclerotic plaques are also characterized by accumulation
of oxidized low-density lipoproteins [93]. In this context, oxLDL is
mostly enclosed in immune complexes containing antibodies
directed against it [93]. Sheedy and colleagues showed that oxLDL
both primed and activated the inﬂammasome in mouse BMDMs.
They proposed a mechanism where the heterotrimeric CD36-
TLR4-TLR6 complex is required for priming. CD36 also mediates
uptake of oxLDL in macrophages, promoting the accumulation of
intracellular crystals that activate NLRP3 inﬂammasome [94].
However, Rhoads et al. failed to replicate these ﬁndings in
BMDMs, where they showed that only oxLDL immune complexes
(and not oxLDL alone) can act as a priming signal for NLRP3, but
conﬁrmed the role of oxLDL in NLRP3 inﬂammasome priming in
bone-marrow-derived dendritic cells [95]. Differences in experi-
mental conditions and methods of oxLDL production may account
for this inconsistency.
2.4. Activation stimuli of NLRP3 inﬂammasome and their roles in
atherogenesis (Figs. 1 and 2, and Table 3)
One of the initial triggers of NLRP3 inﬂammasome activation in
the context of atherosclerosis may be the oscillatory shear force
acting on the endothelium to induce SREBP2 activation, which
transcriptionally stimulates NLRP3 [12]. This stimulus acts both as
a priming and an activating signal, resulting in a marked pro-
inﬂammatory response in endothelial cells [12]. SREBP2 can also
be activated in response to phospholipid oxidation products [96].
Besides, the presence of cholesterol crystals in the athero-
sclerotic region of the vessel is thought to be a major trigger of
NLRP3 activation in macrophages [42,91]. Small crystals may
already be present at the early stages of atherosclerotic lesions
and become abundant in advanced lesions. They represent a
major factor of plaque vulnerability and trigger inﬂammasome
activation by inducing lysosomal damage [3]. This results in dose-
dependent secretion of IL-1b [3]. Recent evidence suggests an
important role for the complement system in cholesterol-
mediated inﬂammasome activation, showing that, in a human
whole blood model, cholesterol crystals activate the classical and
alternative complement pathways, and that presence of C5 is
necessary for Caspase-1 activation [97].
After its recognition as a danger and priming signal by scav-
enger receptor CD36 together with the TLR heterodimer formed
by TLR4 and TLR6, oxLDL endocytosis through CD36 leads to its
intracellular nucleation into cholesterol crystals, resulting in
Fig. 1. Inﬂammasome priming and activation signals during atherogenesis.
Multiple stimuli may prime NLRP3 inﬂammasome in the context of atherosclerosis. Non-transcriptional priming is mediated by MyD88, which deubiquitinates NLRP3 upon TLR4
activation. Transcriptional priming occurs via the transcription factor NF-kB and results in an increase of the expression levels of NLRP3 and pro-IL-1b. NLRP3 activation is mediated
mainly by ATP, oxLDL and cholesterol crystals. To date, the precise mechanisms that lead to activation of NLRP3 inﬂammasome in this context have not fully been deﬁned. However,
ROS production, potassium efﬂux and lysosomal damage are known key players in this process.
M. Baldrighi et al. / Atherosclerosis 267 (2017) 127e138132lysosomal damage and NLRP3 activation [94]. Additionally, CD36
expression is increased by cholesterol crystals via activation of the
BTK-p300-STAT1-PPARg signalling cascade [98], promoting further
intake of oxLDL. Therefore, uptake of lipids and their derivatives
substantially contributes to inﬂammasome activation and IL-1
release by the immune cells of the developing atherosclerotic
lesions.
Metabolites such as extracellular ATP, a classical non-lipid
danger stimulus, are released as a consequence of cell death.Therefore, they are also present in the atherosclerotic plaque
environment, and are responsible for further activation of the im-
mune response (immunogenic cell death) [99]. ATP mediates
NLRP3 inﬂammasome activation in macrophages through activa-
tion of the purinergic receptor P2X7R, promoting pro-
inﬂammatory cytokines release [33]. Knock-down of P2X7R in
Apoe/ mice [64] or its knock-out in Ldlr/ mice [100] reduced
inﬂammasome activation and the development of atherosclerosis.
High serum uric acid levels are associated with the presence of
Fig. 2. Hematopoietic clonal expansion drives NLRP3 inﬂammasome priming and
activation during atherosclerosis.
Loss of function TET2 mutations in hematopoietic cells can drive clonal expansion,
and accelerate the development of atherosclerotic plaques in a NLRP3 inﬂammasome
dependent manner. However, the mechanisms linking clonal expansion of myeloid
cells to NLRP3 priming and activation are still unknown.
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M. Baldrighi et al. / Atherosclerosis 267 (2017) 127e138 133atherosclerotic plaques [101], and uric acid crystals MSU are
known activators of NLRP3 inﬂammasome [43]. Recent evidence
suggests that soluble uric acid can also trigger NLRP3-dependent
IL-1b release in bone marrow-derived macrophages in a mito-
chondrial ROS-dependent mechanism [102].
Interestingly, activated macrophages release IL-1a and High-
mobility Group Box Protein 1 (HMGB1) in a NLRP3-dependent
mechanism that does not require Caspase-1 [74,103e105]. Both
IL-1a and HMGB1 are alarmins, i.e. prototypical danger signals
that induce pro-inﬂammatory cytokine release from macro-
phages, and affect atherosclerosis progression [106,74]. These
results suggest that NLRP3 inﬂammasome might regulate
atherogenesis through functions which are independent from IL-
1b, IL-18 and Caspase-1.
Human studies have shown that aging is associated withT K
M. Baldrighi et al. / Atherosclerosis 267 (2017) 127e138134increased prevalence of hematopoietic stem cell mutations, which
are linked with progressive and acquired clonal expansion, and are
a risk factor for atherosclerotic disease [107e109]. Some of those
somatic mutations lead to loss of function of TET2, an epigenetic
modiﬁer enzyme. Interestingly, clonal hematopoiesis associated
with Tet2 deﬁciency accelerates the development of atherosclerosis
in mice. Tet2/ macrophages localizing in atherosclerotic lesions
have increased inﬂammasome activation, associated with
increased IL-1b release. Their presence is associated with greater
atherosclerotic plaque size [110,109]. This effect is abrogated by
administration of the NLRP3 inﬂammasome inhibitor MCC950
[110,111]. However, the molecular mechanisms linking TET2 or
clonal expansion of myeloid cells to NLRP3 priming and activation
are still unknown.2.5. Molecular and cellular pathways involved in the regulation of
NLRP3 activity during atherosclerosis
Cholesterol crystal-mediated NLRP3 activation has been shown
to result in the production of ROS via a mechanism that requires
NADPH and xanthine oxidase [98], leading to subsequent pro-
inﬂammatory responses and increased CD36 expression.
Increased CD36 expression may positively feedback to promote
more intracellular nucleation of cholesterol crystals and NLRP3
activation [94]. Besides cholesterol crystal formation, cellular
cholesterol and (phospho)lipid levels per se play an important role
in the regulation of inﬂammasome activation. Indeed, low mem-
brane cholesterol levels result in higher ion currents through P2X7
channels in macrophages [112]. Lipin-2 enzyme regulates lipid
concentrations and is crucial to maintain correct currents through
P2X7 channels. Lipin-2 also regulates pro-IL-1b levels upon priming
of macrophages, with a mechanism that involves MAPKs [112]. A
speciﬁc MAPK, p38d, has been identiﬁed as an important regulator
of inﬂammasome activation within atherosclerotic lesions [113].
Also, regardless of the presence of cholesterol crystals, mtDNA-
induced mitochondrial dysfunction can drive atherosclerosis [114].
Recent evidence shows that Ldlr/ mice depleted from OGG, an
enzyme that removes damaged mtDNA from atherosclerotic pla-
ques, show higher inﬂammasome activation and bigger plaques
[115]. Lectin-like ox-LDL receptor-1 (LOX-1) is a major receptor for
ox-LDL that plays a key role in several inﬂammatory disease states.
LOX-1 activation following a pro-inﬂammatory signal leads to ROS
generation and mtDNA damage and eventually to xanthine-
oxidase-mediated NLRP3 inﬂammasome activation [116].
Furthermore, growing evidence supports the role of endo-
plasmic reticulum stress in atherosclerosis progression [117,118].
The conserved mediator of homeostasis in the unfolded protein
response (UPR) IRE1 plays an important role in this process. The
enzyme IRE1 regulates pro-atherogenic genes and is activated in
macrophages upon exposure to excessive amounts of lipids, leading
to activation of NLRP3 inﬂammasome through production of ROS
[119,120]. Consistent with this notion, the use of the IRE1 inhibitor
in a Apoe/ mouse model challenged with a western diet, resulted
in a reduction of the size of atherosclerotic plaques through
reduced macrophage accumulation and activation [119]. Palmito-
leate is a bioactive lipid that prevents lipid-induced activation of
the inﬂammasome in macrophages through its role in ER mem-
brane remodelling, which results in attenuation of ER stress in vivo
in an Apoe/ mouse model, leading to a reduction in atheroscle-
rotic plaque size [39]. However, the evidence for a direct connection
between ER stress and inﬂammasome activation during athero-
sclerosis needs to be explored further.3. Control of NLRP3 activity during atherogenesis
Current drugs with potential impact on NLRP3 activation during
atherogenesis include known drugs such as colchicine and statins.
New drugs with capacity to regulate NLRP3 activity and disrupt
cholesterol crystal formation have also been explored. However,
most of these agents remain at the stage of either in vitro assays or
in vivo experimentation in pre-clinical atherosclerosis models with
limited data. Thus, further exploration is needed to conﬁrm the
effect of these agents on the development of atherosclerosis.3.1. Therapies that may display inhibitory effects on NLRP3
inﬂammasome (Table 4)
Statins are structural analogues of HMG-CoA used in the phar-
macological management of hyperlipidemia. They cause partial
inhibition of HMG-CoA reductase, blocking the ﬁrst committed step
of the synthesis of endogenous sterols. Statins are most effective in
reducing LDL levels through reduction of cholesterol synthesis and
an increase in LDL receptor levels, leading to increased LDL clear-
ance from plasma. Besides their effects on cholesterol levels, statins
may exert direct immune modulatory effects. Atorvastatin, a
commonly prescribed statin, inhibits TLR4/MyD88/NF-kB depen-
dent NLRP3 expression in THP-1 cells in vitro, and consequently
reduces IL-1b secretion [121].
The alkaloid colchicine is an established treatment for gout, and
more recent studies also highlighted the potential of this com-
pound in the management of atherosclerosis and the secondary
prevention of cardiovascular events [122]. Colchicine disrupts
inﬂammasome activation by preventing microtubule assembly
[123]. Microtubule integrity is important for inﬂammasome acti-
vation, which requires precise spatial arrangement of speciﬁc
subcellular compartments [48]. In cultured ATP-stimulated mono-
cytes derived from acute coronary syndrome patients treated with
colchicine, the drug was effective in reducing inﬂammasome-
dependent inﬂammation. Moreover, colchicine acutely sup-
pressed local cardiac production of IL-1b in patients with acute
coronary syndromes [124].
Arglabin, a plant-derived sesquiterpene lactone tested for its
anti-inﬂammatory and anti-tumour activities, has recently been
shown to inhibit NLRP3 and reduce atherosclerotic lesion size in an
ApoE2 knock-in mouse model [125].3.2. Other agents that can suppress cholesterol crystal-induced
NLRP3 inﬂammasome activation (Table 3)
Evidence in an Apoe/ mouse model suggests that increasing
cholesterol solubility with ursodeoxycholic acid leads to a reduc-
tion in atherosclerotic plaque size [126]. In the same mouse model,
cyclodextrin reduces the formation of atherosclerotic plaques and
promotes the regression of existing plaques [127]. Ethanol has been
shown to reduce cholesterol crystal-induced NLRP3 inﬂammasome
activation in primary human macrophages with consequent
reduction of IL-1b secretion, by ameliorating lysosomal integrity
[128]. Febuxostat, a xanthine oxidase inhibitor, protects against
cholesterol crystal-induced ROS formation in vitro, and reduces
atherosclerosis progression in an Apoe/ mouse model [129].
Finally, HDL-cholesterol suppress cholesterol crystal-induced
release of IL-1b in THP1 cells and in monocyte-derived macro-
phages [130]. HDL-cholesterol modulates the inﬂammasome by a
combination of different mechanisms [130]: the main one consists
in modulation of the expression of NLRP3 and pro-IL-1b by
decreasing NF-kB signalling; moreover, HDL binds to cholesterol
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M. Baldrighi et al. / Atherosclerosis 267 (2017) 127e138 135crystals, sequestering them and preserving lysosomal membrane
integrity upon phagocytosis of cholesterol crystals; in vivo, HDL
reduces monocyte recruitment to sites of inﬂammation.
4. Clinical trials targeting NLRP3 pathway in atherosclerotic
patients
The discovery of the inﬂammasome has been quickly trans-
ferred from bench to bedside. In the cardiovascular research ﬁeld,
Abbate et al. conducted randomized double-blind pilot trials in
acute myocardial infarction (MI) patients [131], and demonstrated
that administration of IL-1 receptor antagonist (IL1RA) was safe and
favourably affected left ventricular remodelling. However, short-
term treatment (14 days) with IL-1RA in patients with non-ST
elevation acute coronary syndromes did not result in sustained
reduction of inﬂammatory markers and was even associated with
signiﬁcant excess of major adverse cardiovascular events after 1
year of follow-up [132]. A trial, named Canakinumab Anti-
inﬂammatory Thrombosis Outcomes Study (CANTOS trial), evalu-
ated the impact of IL-1b blockade on the occurrence/recurrence of
cardiovascular events (myocardial infarction, stroke, and cardio-
vascular death) among 17,200 stable coronary artery disease pa-
tients who are at high vascular risk [133,134]. Canakinumab is a
human monoclonal antibody that selectively neutralizes IL-1b.
CANTOS evaluated three active doses of canakinumab in compari-
son to placebo. Preliminary data already supported the use of anti-
IL-1b antibody as a potential therapeutic method as it signiﬁcantly
reduces inﬂammation [135], although it did not seem to affect
vascular structure or function in those patients [136]. The results of
CANTOS have been published recently. CANTOS met the primary
endpoint, reducing the risk of major adverse cardiovascular events,
a composite of cardiovascular death, non-fatal myocardial infarc-
tion and non-fatal stroke [134]. However, therewas no difference in
all-cause mortality, and canakinumab treatment was associated
with a higher incidence of fatal infection compared to placebo. The
trial expands our understanding of how the balance of innate im-
munity contributes to cardiovascular health, and provides critical
safety and efﬁcacy data on long-term inhibition of IL-1b dependent
immunity.
5. Perspectives
In order to provide future reliable therapeutic strategies for
atherosclerosis based on modulation of the inﬂammasome
pathway, we still have to delineate a vast number of unknown
mechanisms in NLRP3 activation, and how NLRP3 pathway entan-
gles with other inﬂammatory pathways to contribute to athero-
sclerotic lesion development.
Compared with simplistic cell culture experiments based on
sequential stimulation of TLRs and NLRP3 inﬂammasome in vitro,
several ligands and stimuli for TLR and NLRP3 inﬂammasome
pathways will co-exist in vivo during atherosclerosis development.
The downstream effects of those signals would not be arranged in a
sequential way as modelled by in vitro assays. Pro-inﬂammatory
stimuli/mediators with activatory and inhibitory properties on
NLRP3 inﬂammasome will co-exist. This is the case of IFNg, a
cytokine that displays pro-atherogenic activity [137] but is a potent
inhibitor of NLRP3 inﬂammasome [25]. Therefore, caution and
improved understanding of the modulators of NLRP3 inﬂamma-
some are needed for a better and safe targeting of the inﬂammatory
response in atherosclerosis.
TLR signalling and NLRP3 inﬂammasome shape microbiota, and
those pathways play key roles in the regulation of intestinal ho-
meostasis [138,139]. In addition, infections and diets have been
linked with the development of chronic and systemic inﬂammation
M. Baldrighi et al. / Atherosclerosis 267 (2017) 127e138136[140]. In turn, gut microbiota andmetabolites of diets can inﬂuence
atherosclerosis. Controversial ﬁndings regarding the role of NLRP3
in experimental atherosclerosis using Ldlr/ or Apoe/ models
[3,79], and distinct contributions of IL-1a or IL-1b towards vascular
inﬂammation [3,74] may result from differences in the basal status
of microbiota, and the diets that can inﬂuence the response.
Furthermore, NLRP3 inﬂammasome is likely to play distinct
roles in different cell types at various stages of lesion development.
For example, work from Owen's lab demonstrates that IL-1 con-
tributes to outward vessel remodelling and enhances features of
plaque stability, which is beneﬁcial for lesion repair [80], suggest-
ing that IL-1might play distinct and sometimes opposite roles by its
effect on smooth muscle cells at late stage of atherosclerosis. Work
from Kemper's lab shows that complement-driven NLRP3 activity
in T cells leads to autocrine IL-1b dependent Th1 differentiation
[15], whereas Ghiringelli and colleagues identiﬁed a requirement
for nuclear NLRP3 in Th2 differentiation, independently of inﬂam-
masome activation [14]. Whether such mechanisms operate in T
cells during atherosclerosis is not yet explored. Thus, more research
on the effect of cell-type speciﬁc roles of NLRP3 during the different
stages of atherosclerosis is required.
Current therapies targeting inﬂammasome activation are
focusing directly on one of the end products of the pathway by
blocking the function of IL-1. However, IL-1 may be generated
downstream of many inﬂammasomes. Global interference with
inﬂammasome-induced innate immunity, by direct and generic
targeting of IL-1, may increase susceptibility to (opportunistic) in-
fections. Thus, a better and more speciﬁc targeting of NLRP3 is
needed.
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